Common Contracts
10 similar null contracts by Sunesis Pharmaceuticals Inc, Five Prime Therapeutics Inc, Chimerix Inc, others
WARRANT TO PURCHASE SHARES OF PREFERRED STOCK January 21, 2005Portola Pharmaceuticals Inc • November 6th, 2013 • Pharmaceutical preparations • California
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase shares of the fully paid and nonassessable Preferred Stock (the “Shares” or the “Preferred Stock”) of Portola Pharmaceuticals, Inc., a Delaware Corporation (the “Company”), to be issued in the Company’s next Qualifying Equity Round (i.e., an equity financing of greater than $5,000,000, primarily from institutional venture investors), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Preferred Stock” shall mean the authorized Series of Preferred Stock associated with the Company’s next Qualifying Equity Round and any stock into which such Series of Preferred Stock may hereafter be converted or exchanged.
No. PAW – 6 WARRANT TO PURCHASE 28,350 SHARES OF SERIES A PREFERRED STOCKFive Prime Therapeutics Inc • July 26th, 2013 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase Twenty-Eight Thousand Three Hundred Fifty (28,350) shares of the fully paid and nonassessable Series A Preferred Stock (the “Shares” or the “Preferred Stock”) of Five Prime Therapeutics, Inc., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Series A Preferred Stock” shall mean the Company’s presently authorized Series A Preferred Stock and any stock into which such Series A Preferred Stock may hereafter be converted or exchanged.
No. PAW – 6 WARRANT TO PURCHASE 28,350 SHARES OF SERIES A PREFERRED STOCKFive Prime Therapeutics Inc • June 14th, 2013 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase Twenty-Eight Thousand Three Hundred Fifty (28,350) shares of the fully paid and nonassessable Series A Preferred Stock (the “Shares” or the “Preferred Stock”) of Five Prime Therapeutics, Inc., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Series A Preferred Stock” shall mean the Company’s presently authorized Series A Preferred Stock and any stock into which such Series A Preferred Stock may hereafter be converted or exchanged.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN...Chimerix Inc • March 8th, 2013 • Pharmaceutical preparations • Connecticut
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase Twenty One Thousand (21,000) shares of the fully paid and nonassessable Series B-l Preferred Stock (the “Shares” or the “Preferred Stock”) of CHIMERIX, INC., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Series B-l Preferred Stock” shall mean the Company’s presently authorized Series B-l Preferred Stock and any stock into which such Series B-l Preferred Stock may hereafter be converted or exchanged.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN...Merrimack Pharmaceuticals Inc • July 8th, 2011 • Connecticut
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase One Thousand Thirty Three (1,033) shares of the fully paid and nonassessable Series C Convertible Preferred Stock (the “Shares” or the “Preferred Stock”) of Merrimack Pharmaceuticals, Inc., a Massachusetts corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Preferred Stock” shall mean the Company’s presently authorized Series C Convertible Preferred Stock and any stock into which such Series C Convertible Preferred Stock may hereafter be converted or exchanged.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN...Sunesis Pharmaceuticals Inc • March 29th, 2011 • Pharmaceutical preparations • Connecticut
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase One Thousand Five Hundred Twenty Four (1,524) shares of the fully paid and nonassessable Series C Preferred Stock (the “Shares” or the “Preferred Stock”) of Sunesis Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Series C Preferred Stock” shall mean the Company’s presently authorized Series C Preferred Stock and any stock into which such Series C Preferred Stock may hereafter be converted or exchanged.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN...Transmedics Inc • September 14th, 2007 • Delaware
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase up to Eighty Thousand (80,000) shares (the “Shares”) of the fully paid and nonassessable Series B Convertible Preferred Stock, $0.0001 par value per share (the “Preferred Stock”) of TransMedics, Inc., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Series B Preferred Stock” shall mean the Company’s presently authorized Series B Preferred Stock and any stock into which such Series B Preferred Stock may hereafter be converted or exchanged.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN...Sunesis Pharmaceuticals Inc • April 29th, 2005 • Pharmaceutical preparations • Connecticut
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase One Thousand Four Hundred Thirty Five (1,435) shares of the fully paid and nonassessable Series C-1 Preferred Stock (the “Shares” or the “Preferred Stock”) of Sunesis Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Series C-1 Preferred Stock” shall mean the Company’s presently authorized Series C-1 Preferred Stock and any stock into which such Series C-1 Preferred Stock may hereafter be converted or exchanged.
WARRANT TO PURCHASE 3,000 SHARES OF SERIES C-1 PREFERRED STOCKSunesis Pharmaceuticals Inc • December 23rd, 2004 • Connecticut
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase Three Thousand (3,000) shares of the fully paid and nonassessable Series C-1 Preferred Stock (the “Shares” or the “Preferred Stock”) of Sunesis Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Series C-1 Preferred Stock” shall mean the Company’s presently authorized Series C-1 Preferred Stock and any stock into which such Series C-1 Preferred Stock may hereafter be converted or exchanged.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN...Sunesis Pharmaceuticals Inc • December 23rd, 2004 • Connecticut
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase One Thousand Four Hundred Thirty Five (1,435) shares of the fully paid and nonassessable Series C-1 Preferred Stock (the “Shares” or the “Preferred Stock”) of Sunesis Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Series C-1 Preferred Stock” shall mean the Company’s presently authorized Series C-1 Preferred Stock and any stock into which such Series C-1 Preferred Stock may hereafter be converted or exchanged.
